News | April 16, 2009

Endeavor Stent Showed Lower Death, MI Rates in ZEST Study Over Taxus Liberte

The Endeavor DES

April 16, 2009 -Twelve-month data from the ZEST trial presented at ACC 2009 showed the Endeavor Drug-Eluting Stent (DES) from Medtronic Inc. was associated with a statistically significant 29 percent reduction in a composite primary endpoint of death, myocardial infarction (MI) and in ischemia-driven target vessel revascularization (TVR), when compared to the Taxus Liberte DES.

The study also found Endeavor was non-inferior to the Cypher Sirolimus-eluting stent on the same primary endpoint.

The Taxus Liberte was shown in this randomized, controlled trial to be associated with a 25 percent increase in death and MI, and a 32 percent increase in the need for repeat revascularization when compared to the Endeavor, Medtronic pointed out in trial data.

The multi-center, Korean study also reported 12-month data on the rate of stent thrombosis (ST) for the three stents. ST is a rare, but frequently fatal event for which no randomized, controlled study to date has been powered to analyze. The first trial to make such a stent thrombosis comparison will be Medtronic's PROTECT study of 8,800 patients in which the Endeavor stent will be compared to the Cypher at three years. Medtronic initiated this study in October 2006 following analysis of data pooled from the clinical programs of both Endeavor and Cypher, in which the rate of ST with Endeavor virtually halts at one-year post implant, whereas the rate with Cypher, and other DES for which data are available, shows a consistent 0.3-0.6 percent annual increase, Medtronic said.

The ST rate appears broadly consistent for all stents in the first year, but the rarity of the event has led to considerable inter-trial variation in rates reported at 12-months. After one year, available data suggest a marked long-term advantage for Endeavor. The rates of stent thrombosis observed in the ZEST study were low, consistent with those observed in other studies and similarly inconclusive.

For more information: www.cordis.com, www.medtronic.com, www.bostonscientific.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init